PPIDT00486
Drug Information
| Name | Epcoritamab |
|---|---|
| Sequence | EVKLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKSSLYLQMNNLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG |
| DrugBank_ID | DB16672 |
| Type | biotech |
| Indication | Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.[L46516,L49459] Epcoritamab is also indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.[L51214] These indications are approved under accelerated approval based on response rate and durability of response. Their continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
4 mg/0.8mL
|
| Injection, solution | Subcutaneous |
48 mg/0.8mL
|
| Solution | Subcutaneous |
4.000 mg
|
| Solution | Subcutaneous |
5 mg / mL
|
| Solution | Subcutaneous |
60 mg / mL
|
| Injection, solution | Subcutaneous |
48 mg
|
| Injection, solution, concentrate | Subcutaneous |
4 mg/0.8ml
|